Q-omics provides the consensus-scored TDO2 profile across patient tissues and cancer cell-line models. TDO2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TDO2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TDO2 RNA expression shows 16,512 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where TDO2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TDO2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TDO2 survival associations across molecular data types. TDO2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TDO2 RNA expression–survival associations across cancer types. High TDO2 expression shows unfavorable associations in KIRP, KIRC, UVM, CESC, ACC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TDO2 RNA expression.
This table summarizes TDO2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TDO2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TDO2 shows lower tumor expression in LIHC and higher tumor expression in HNSC, BLCA, LUAD, KIRC and COAD. The HNSC box plot shows higher TDO2 RNA expression in tumor versus normal tissue (log2 FC = +1.602, t-test p < 0.001).
This table shows molecular features associated with TDO2 in patient tissues and cancer cell lines. In patient samples, TDO2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TDO2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
